The total biopharmaceutical manufacturing market is growing, according to Kalorama Information's report, Biopharmaceutical and Vaccine Production Markets. The market research publisher includes all costs related to biopharmaceutical and vaccine manufacturing in its estimates. The total global market equaled approximately $36.8 billion in 2013, with the high expense of adding biomanufacturing capacity at commercial production levels driving demand for specialized contract manufacturing, which is expected to grow due to new drug commercialization, recovered investment funding rates for biotechnology companies, and expanding service offerings for novel therapeutics.
"At this cost level, novel technologies and outsourcing are essential to strategy," said Bruce Carlson, Publisher of Kalorama Information. "Fortunately, this means a lot of opportunity for companies that can service these needs."
The market research publisher's report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. Despite the proliferation of novel production technologies, commercial scale systems based on the familiar mammalian cells and E. coli are expected to continue to dominate the manufacturing scene through the end of 2018.
Biopharmaceutical and Vaccine Production Markets notes the current competitive environment, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Profiles of key competitors are also included.
Can soda taxes fight obesity? New research adds to the debate